Currently browsing: Community News

Assorted News from the Last Week: Congratulations to CAC2 Supporting Organization Day One Biopharmaceuticals.  The FDA has granted accelerated approval to tovorafenib (Ojemda) for the treatment of pediatric patients 6 months of age and older with relapsed or refractory low-grade glioma harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation and marks the first systemic therapy indicated for pediatric patients with low-grade glioma harboring BRAF rearrangements, including fusions.  There are a ton of articles about this approval.  This OncLive piece was the first in. The FDA approved lutetium Lu 177 dotatate for the treatment of pediatric patients aged 12 [...] Read more

Assorted News from the Last Week: To achieve successful socioeconomic reintegration in the long term, it is crucial to implement a childhood cancer survivorship program that addresses the unique needs of individuals based on their disease and cultural background throughout their entire lives. Data sharing platforms for precision care can revolutionize the way we treat patients and advance treatments and cures for pediatric brain cancer. Following a progressive expansion, the ZERO Childhood Cancer program is now available to all children with cancer in Australia. This means that every child, regardless of their cancer type or risk profile, will now have [...] Read more

Assorted News from the Last Week: The UK's National Institute for Health and Care Excellence (NICE) recommended Novartis' autologous CAR T-cell therapy Kymriah (tisagenlecleucel) for children and young adults with previously treated B-cell acute lymphoblastic leukemia (ALL). CAC2 Supporting Member Oncoheroes Biosciences has been chosen as one of the eleven finalists for the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit. Scheduled for May 14th–15th, 2024, at the Cleveland Clinic Abu Dhabi, this event aims to cultivate a thriving ecosystem for early-stage entrepreneurs in the life sciences sector. Researchers have identified new variations in neuroblastoma that could lead to [...] Read more

Assorted News from the Last Week: FDA announced its Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee will meet virtually on 22 May to discuss provisions in the 2017 FDA Reauthorization Act that require sponsors of adult cancer drug premarket applications to also submit data that could be used to inform the use of the drug in children. The subcommittee is expected to meet to discuss implementing the law and how it could affect pediatric cancer drug development. In honor of National AYA Cancer Awareness Week, please note the recent announcement from the White House about patient data portability: [...] Read more

Assorted News from the Last Week: Cancer is far more likely to be caused by “tumor-suppressor” genes than by one gene run amok.  Interestingly, last week Nature reported that researchers from St. Jude had stumbled on a new way of treating cancers caused by malfunctioning tumor-suppressor genes.  Their work focuses on a rare and aggressive childhood cancer called rhabdoid tumors and is based on restoring the broken tumor suppressor system, reverting malignant cells into ordinary ones. Longer duration of exclusive breastfeeding was associated with a reduced risk of childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL), according to results from a [...] Read more

Assorted News from the Last Week: The White House Office of Science and Technology Policy (OSTP) has announced that the Pediatric Cancer Data Commons (PCDC) at the University of Chicago is one of five winners of the 2023 OSTP Year of Open Science Recognition Challenge. More than 90% of pediatric patients with cancer will experience hair loss; but in a recent study, topical minoxidil increased hair growth (hair density and thickness) in 87% of pediatric patients with chemotherapy-induced alopecia. Doxorubicin, a common chemotherapy drug used to treat Hodgkin lymphoma conferred a significantly increased risk of breast cancer among women treated [...] Read more

Assorted News from the Last Week: Feature story about CAC2 Member Beat Childhood Cancer and new FDA approved therapeutic DFMO:  Families of paediatric cancer patients have helped move a pioneering treatment for neuroblastoma from the lab to the clinic. Could this breakthrough accelerate the development of future treatments? Individuals with tooth agenesis may be more likely to develop several different cancer types from childhood through young adulthood. Surveillance for late effects in adult survivors of childhood cancer is poor, placing many survivors at risk for preventable harm. To increase surveillance among this elevated-risk population, screening recommendations need to consider and [...] Read more

Assorted News from the Last Week: Cancer Grand Challenges has selected five new global research teams that will address the following challenges in cancer.  This year two teams working to develop drugs for solid tumors in children were selected.  The teams will use protein degradation strategies to target previously undruggable drivers of childhood cancers. The latest Childhood Cancer Data Initiative (CCDI) resource is the Childhood Cancer Clinical Data Commons (C3DC), an open-access web application with harmonized childhood cancer demographics and phenotypic clinical data.  Use this resource to search for participant-level data, create synthetic cohorts, and export data from the Molecular [...] Read more

Assorted News from the Last Week: Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada. President’s Cancer Panel Initial Assessment of the National Cancer Plan: A Report to the President of the United States Remembering Alea Christine Ramsey – a young woman who touched many hearts. CAC2 Supporting Organization Day One Biopharmaceuticals gears up for breakthrough in pediatric cancer treatment with promising financials and FDA nod. Innovations in pediatric brain cancer treatment: A leap towards preserving childhood Pediatric cancers, like all rare conditions, will benefit from a ‘Warp Speed’ Mindset 6 biotech companies making a [...] Read more